Friday, September 21, 2012 6:51:34 PM
COTARA-( I131 CH T.N.T.1/B ) is the fusion of a
radioactive particle-( iodine 131 ) and a monoclonal
antibody-( T.N.T. ). Radioactive iodine 131 gives off a
lethal burst of gamma rays within a 300 cell radius. The half life of I131 is approximately 8 days and it does not degrade off the antibody for approximately 10 days.
The Tumor Necrosis Targeting agent-( T.N.T. ) is the vehicle that carries iodine 131 to the cancer cells. because it is a chimeric antibody-( part mouse part human )allergic reactions are minimal. T.N.T. homes in on necrotic tissue found in the core of all solid based tumors. Cancer cells have leaky spots that allows
Cotara entrance-(normal cells do not ). Cotara is too large to fit through the outer membrane of a normal cell-( which also has some but relatively small amounts of necrotic tissue at its core ). Cotara is unique in that it is the only therapeutic agent that will attack ANY solid based tumor large enough to have a necrotic core and leave healthy tissue alone. Other monoclonal antibody therapies are geared for particular cancers - Cotara will seek out and deliver its deadly cargo to ALL solid based tumors.
Many monoclonal antibodies rely on finding and latching
on to specific docking sites found on the surface of cancer cells. If the antibody does not " overwhelm " the tumor then the disease is poised for a comeback. If the docking sites are used up and/or cell surface mutations have altered the sites then what at first appeared to be an effective modality will now be relatively useless. In contrast Cotara becomes more effective with each subsequent dose, since after each application more and more necrotic tissue forms thus presenting a larger and larger target.
Because our docking site is at the core of the tumor the problems associated with the lack of cell surface docking sites and/or mutations are eliminated.
Cotara does not merely interfere with cellular machinery. It is a powerful treatment that will incinerate more and more of the tumor from the inside out -( and send those toxic cells back into hell where they belong ).
According to Dr.Patel there has been some swelling associated with Cotara when used in treating a form of brain cancer. The problem was however manageable when steroids were used.
M.A.T.-( MODIFIED ANTIBODIES TECHNOLOGY) I copied this from an old Yahoo post. This is the "B" in
I131 CH T.N.T./B.
by: ownotshort (64/M/Seattle,WA) 07/19/99 01:20 pm
Msg: 27817 of 256647
" Techniclone scientists discovered that when a small organic molecule like the vitamin biotin is attached to a monoclonal antibody it decreases its electrical charge. Decreasing the electrical charge of the antibody dramatically influences the way the antibody travels in the blood stream. The positive electrical charge of an un-modified antibody gives it a sticky characteristic that causes it to stick to capillary walls as it passes through the blood stream. This stickiness causes delayed antibody circulation, decreased tumor uptake and increased antibody clearance time (time it takes the antibody and toxic payload to clear from the blood stream). Increased clearance time results in higher toxicity.
Decreasing the antibody clearance time may dramatically reduce the toxicity of many, if not most, monoclonal antibody/toxic drug therapies. The increase in monoclonal antibody uptake at the tumor site should result in an increase in drug efficacy. Monoclonal antibodies using TCLN s MAT clear from the bloodstream in half of the time of normal antibodies and produce a 2-3-fold increase in antibody/tumor uptake.
Recent CDMO News
- Avid Bioservices to Participate in Craig-Hallum Bioprocessing Conference • GlobeNewswire Inc. • 09/12/2024 08:05:27 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 09/09/2024 08:43:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/09/2024 08:19:30 PM
- Avid Bioservices Reports Financial Results for First Quarter Ended July 31, 2024 • GlobeNewswire Inc. • 09/09/2024 08:05:31 PM
- U.S. Futures Rise Amid Inflation Report Anticipation; Oil Prices Climb on Hurricane Threat and Supply Concerns • IH Market News • 09/09/2024 10:09:14 AM
- Avid Bioservices to Report Financial Results for First Quarter of Fiscal Year 2025 After Market Close on September 9, 2024 • GlobeNewswire Inc. • 09/03/2024 08:05:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/29/2024 08:30:10 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 08/28/2024 08:34:04 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 08/28/2024 08:32:18 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 08/28/2024 08:30:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/16/2024 11:50:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/16/2024 11:48:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/15/2024 08:40:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/12/2024 08:30:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:02:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:02:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:01:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:01:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:00:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:00:45 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/11/2024 12:23:26 AM
- Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2024 • GlobeNewswire Inc. • 07/02/2024 08:05:04 PM
- Avid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2024, After Market Close on July 2, 2024 • GlobeNewswire Inc. • 07/01/2024 11:00:21 AM
- Avid Bioservices Earns Committed Badge from EcoVadis for Sustainability Performance • GlobeNewswire Inc. • 05/23/2024 12:05:46 PM
- Avid Bioservices to Participate at Upcoming Investor Conferences • GlobeNewswire Inc. • 05/07/2024 08:05:11 PM
FEATURED CBD Life Sciences, Inc. (CBDL) Reaches Unprecedented Heights With Explosive Growth and Strategic Expansion in 2024 • Oct 8, 2024 8:00 AM
BNCM COMPLETES MERGER WITH DELEX HEALTHCARE • BNCM • Oct 8, 2024 9:54 AM
Unitronix Corp. to Invest $3 Million in USA Unity Coin Project • UTRX • Oct 7, 2024 7:08 AM
North Bay Resources Announces Assays up to 5 oz/ton Gold, 1.5 oz/ton Platinum, 0.5 oz/ton Palladium, and 0.5 oz/ton Rhodium at Mt. Vernon Gold Mine, Sierra County, California • NBRI • Oct 4, 2024 9:15 AM
Basanite, Inc. Appoints Ali Manav as Interim Chief Executive Officer • BASA • Oct 3, 2024 9:15 AM
Integrated Ventures Announces Launch of MedWell Facilities, LLC and Lease Agreement with Giant Fitness Clubs • INTV • Oct 3, 2024 8:45 AM